blog
April 18, 2022 | Source: Rapid Micro Biosystems, Inc.
Strengthening a Weak Link in QC Microbial Testing (Part II)
POSTED BY Rapid Micro Biosystems | 5 minute read
April 18, 2022 | Source: Rapid Micro Biosystems, Inc.
POSTED BY Rapid Micro Biosystems | 5 minute read
By Mark Newton and David L. Jones
Microbial enumeration testing in the pharmaceutical QC lab is based around well proven traditional manual methods that have changed little since the creation of the first pharmacopeia. These manual processes rely heavily on the training, expertise and judgment of the individuals who perform them. Improvements have been made to the processes to minimize variation such as: use of commercial media, validated incubators, verification signatures and electronic batch records; however, the ability to accurately see and enumerate colonies, then accurately record the information to paper or electronic system, is still a weak link in the forensic data trail.
In this four-part series, we will explore the unprecedented capabilities of automated plate counting: consistent counting, time savings and reduced fatigue for analysts, and automated capturing of complete, original data for review, monitoring and trending analysis. Along the way, we will also suggest key considerations for QC labs evolving from manual plate counts to automation.
The key to mitigating microbiological risks in quality control testing, in addition to increasing efficiency and reducing ergonomic issues, can be found in the use of digital systems. Digital systems offer hands-free, consistent analysis of plates, the capability to save an image of the plate at the time of analysis, and the ability to save a complete record of testing whether passing, failing, or invalid.
Here are just some of the many advantages realized by microbiological laboratories that move forward with digital plate reading and analysis:
In the next post of our four-part series, we will address some key considerations for users of digital plate count systems. Look for it soon!
Mark Newton is an associate senior quality assurance consultant at Eli Lilly and Company. David L. Jones is director of marketing and industry affairs at Rapid Micro Biosystems. This content previously appeared in edited form in the March 2022 issue of Cleanroom Technology.